Microsatellite instability cancer – European Clinical Trials Information Network https://clinicaltrials.eu Bridging Patients with Clinical Trials Wed, 24 Jun 2026 04:11:42 +0000 en-US hourly 1 https://wordpress.org/?v=7.0 https://clinicaltrials.eu/wp-content/uploads/2024/12/cropped-EU_icon-32x32.png Microsatellite instability cancer – European Clinical Trials Information Network https://clinicaltrials.eu 32 32 Study on PET Imaging with Fianlimab and Cemiplimab for Patients with Advanced Solid Tumors, with or without Platinum-Based Chemotherapy https://clinicaltrials.eu/trial/study-on-pet-imaging-with-fianlimab-and-cemiplimab-for-patients-with-advanced-solid-tumors-with-or-without-platinum-based-chemotherapy/ Wed, 29 Apr 2026 15:01:58 +0000 https://clinicaltrials.eu/trial/study-on-pet-imaging-with-fianlimab-and-cemiplimab-for-patients-with-advanced-solid-tumors-with-or-without-platinum-based-chemotherapy/ This clinical trial is focused on studying advanced forms of solid cancer, which can include types like melanoma, non-small-cell lung cancer (NSCLC), cervical cancer, and others. The study involves a new treatment approach using a medication called Fianlimab (also known by its code name REGN3767) and another medication called Cemiplimab. Fianlimab is a type of protein designed to target specific parts of cancer cells, and Cemiplimab is used to help the immune system fight cancer. Some patients may also receive platinum-based chemotherapy, which is a common cancer treatment that uses drugs containing the metal platinum to kill cancer cells.

The purpose of this study is to find the best dose of Fianlimab and the best time to perform a special type of imaging called PET scan to see how the treatment is working. A PET scan is a test that helps doctors see how organs and tissues inside the body are functioning. The study will also look at how safe Fianlimab is for patients. Participants will receive the treatment and undergo PET scans before and during their treatment with Cemiplimab, with or without chemotherapy. The study will help researchers understand how the treatment affects the body and how well it works against the cancer.

Throughout the study, patients will be monitored closely to ensure their safety and to observe any changes in their condition. The study aims to provide valuable information that could lead to better treatment options for people with advanced solid cancers. By understanding how these medications work together, researchers hope to improve outcomes for patients facing these challenging diseases.

]]> Study of Dostarlimab Combined with Short Course Radiotherapy for Locally Advanced Rectal Cancer Patients with Microsatellite Instability https://clinicaltrials.eu/trial/study-of-dostarlimab-and-short-course-radiotherapy-for-patients-with-locally-advanced-rectal-cancer-with-microsatellite-instability-or-mismatch-repair-deficiency/ Wed, 29 Apr 2026 15:01:10 +0000 https://clinicaltrials.eu/trial/study-of-dostarlimab-and-short-course-radiotherapy-for-patients-with-locally-advanced-rectal-cancer-with-microsatellite-instability-or-mismatch-repair-deficiency/ This study focuses on patients with locally advanced rectal cancer that has specific genetic characteristics – microsatellite unstable or mismatch repair-deficient. These terms refer to specific changes in the cancer cells that affect how DNA repairs itself. The study evaluates a treatment approach combining dostarlimab (marketed as JEMPERLI), which is given through intravenous infusion, with a short course of radiotherapy.

The main purpose of this research is to determine how effective this combination treatment is in controlling the cancer without the need for surgery. The treatment involves receiving dostarlimab infusions along with radiation therapy. After treatment, patients will be monitored to see if their cancer completely disappears, which would allow them to avoid surgery.

During the study, patients will receive dostarlimab infusions at a dose of 500 mg for up to 6 months. The effectiveness of this approach will be evaluated over a two-year period to check if the cancer remains controlled without surgery. Doctors will monitor patients’ overall health, how well the cancer responds to treatment, and whether the cancer returns after initial response.

]]> Study of Monalizumab and Volrustomig for Patients with MSI and/or dMMR Metastatic Cancer https://clinicaltrials.eu/trial/study-of-monalizumab-and-volrustomig-for-patients-with-msi-and-or-dmmr-metastatic-cancer/ Wed, 29 Apr 2026 14:57:48 +0000 https://clinicaltrials.eu/trial/study-of-monalizumab-and-volrustomig-for-patients-with-msi-and-or-dmmr-metastatic-cancer/ This clinical trial is focused on studying treatments for patients with a type of cancer known as metastatic cancer that has specific characteristics called MSI (microsatellite instability) and/or dMMR (deficient mismatch repair). These characteristics can make the cancer more challenging to treat. The study will use two medications: Monalizumab and MEDI5752, which is also known as volrustomig. Monalizumab is a type of protein that helps the immune system fight cancer, and MEDI5752 is a specially designed antibody that targets certain proteins on cancer cells to help the immune system attack them.

The purpose of this study is to see how well these two medications work together in treating this type of cancer. Participants in the study will receive these medications through an intravenous infusion, which means the medicine is given directly into a vein. The study will last for up to 24 weeks, during which time the response of the cancer to the treatment will be closely monitored. This will help researchers understand how effective the treatment is and what side effects might occur.

Throughout the study, participants will have regular check-ups and tests, such as MRI scans, to track the progress of the treatment. The study aims to find out if the combination of Monalizumab and MEDI5752 can help control the cancer and improve the quality of life for patients with this challenging condition. Participants will be monitored for any side effects to ensure their safety during the trial.

]]> Study Comparing MK-1308A and Pembrolizumab for Patients with Advanced Colorectal Cancer with High Microsatellite Instability or Mismatch Repair Deficiency https://clinicaltrials.eu/trial/study-comparing-mk-1308a-and-pembrolizumab-for-patients-with-advanced-colorectal-cancer-with-high-microsatellite-instability-or-mismatch-repair-deficiency/ Wed, 29 Apr 2026 14:23:22 +0000 https://clinicaltrials.eu/trial/study-comparing-mk-1308a-and-pembrolizumab-for-patients-with-advanced-colorectal-cancer-with-high-microsatellite-instability-or-mismatch-repair-deficiency/ This clinical trial is focused on studying treatments for Stage IV Colorectal Cancer, specifically in patients with a condition known as Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR). These are specific types of genetic changes in cancer cells that can affect how the cancer grows and responds to treatment. The study will explore the effectiveness of several treatments, including a combination of drugs called MK-1308A (which includes quavonlimab and pembrolizumab), as well as other treatments like MK-4280A, MK-7684A, and MK-4830 combined with pembrolizumab. Pembrolizumab is also being tested on its own.

The purpose of the study is to compare how well these treatments work in shrinking tumors and improving patient outcomes. Participants will receive these treatments through an intravenous infusion, which means the medication is given directly into a vein. The study will be conducted over a period of time, and participants will be monitored to see how their cancer responds to the treatment. The study will also look at how long the response lasts, how long patients live without the cancer getting worse, and overall survival rates.

Throughout the study, the safety of the treatments will be closely monitored, and any side effects will be recorded. The study aims to provide valuable information on the effectiveness of these treatments for patients with this specific type of colorectal cancer, potentially leading to better treatment options in the future.

]]>